Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nusinersen in later-onset Spinal Muscular Atrophy
NCT02292537Phase 3Completed
- Sponsor
- Biogen
- Start
- Nov 2014
- Primary completion
- Feb 2017
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of nusinersen in spinal muscular atrophy (SMA) (2 arms), sponsored by Biogen. Primary endpoint: Change From Baseline in Hammersmith Functional Motor Scale - Expanded Score at Month 15. Started Nov 2014; status: completed.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT02292537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02292537.